Brian Carpenter
CEO and Co-founder @Aboligo
Signup · Get unlimited contacts
WORK HISTORY
CEO and Co-founder @Aboligo
Cambridge, GB
AbOliGo (Cambridge UK, founded 2024) is developing a revolutionary platform for rapid, small-scale production of antibody-oligonucleotide conjugates (AOCs), addressing a critical bottleneck in multiplexing. AOCs are transformative tools that combine antibodies\' exquisite targeting specificity with oligonucleotides\' properties - DNA amplification and molecular barcoding, enabling unlimited multiplexing. However, while there are approximately 7 million commercially available antibodies, only ~0.03% are offered as AOCs.Recognizing the growing demand for AOCs, we aim to innovate and re-imagine the manufacturing process through three key technological advancements: • Scale - A novel conjugation methodology that enables production at µg scale.• Quality – Develop quantitative QC release criteria, guaranteeing batch consistency.• Fast – manufacture and deliver AOCs from a large portfolio within days.
EDUCATION
Newcastle University
BSc - Hons, Molecular Biology
Robert Gordon Univeristy
MBA
University of Dundee
PhD, Cancer Biology - Molecular Mechanisms
SKILLS
ABOUT BRIAN CARPENTER
I am a driven professional with more than 25 years of experience in the life science and biotechnology industries. Through energy, initiative and determination, I have the ability to look at the many complex facets of a company to design business strategies that not only mitigate risks and poor performance; but importantly, drive a business towards continuous growth, sustainability, and increased profitability. Such success is built mainly upon one key criteria, re-engineering companies to be customer focused.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.